---
categories: 
- Database
- Release
date: 2024-06-06
title: Database release
github_url: https://github.com/vanallenlab/moalmanac-db/releases/tag/v.2024-06-06
---
Added entries:
- (FDA) _ALK_ fusions and sensitivity to alectinib for patients with non-small cell lung cancer.
- (FDA) _BRAF_ p.V600E/K (p.V600 variants), rearrangements, and fusions and sensitivity to tovorafenib for patients with low-grade glioma.
- (FDA) _EGFR_ p.L858R and exon 19 deletions and sensitivity to erlotinib for patients with non-small cell lung cancer.
- (FDA) _EGFR_ p.L858R and exon 19 deletions and sensitivity to gefitinib for patients with non-small cell lung cancer.

Revised entries:
- (FDA) _RET_ fusions and sensitivity to selpercatinib for patients with solid tumors is now indicated for pediatric patients aged 2 and older, in addition to adult patients.
- (FDA) _RET_ fusions and sensitivity to selpercatinib for patients with thyroid cancer is now indicated for pediatric patients aged 2 and older, revised from age 12 or older. 
- (FDA) _RET_ variants and sensitivity to selpercatinib for patients with medullary thyroid cancer is now indicated for pediatric patients aged 2 and older, revised from age 12 or older.
- (FDA) _RET_ fusion and sensitivity to selpercatinib for patients with non-small cell lung cancer's description and publication date were revised. 